荧光原位杂交技术在尿路上皮癌筛查中价值  

Value of fluorescence in situ hybridization to the screening of urothelial carcinoma

作　　者：胡桂明[1] 任景丽[1] 王宪远[1] 杜英[2] 杨鲲鹏[3] 

机构地区：[1]郑州大学第二附属医院病理科,郑州450014 [2]郑州大学基础医学院微生物学与免疫学教研室,郑州450001 [3]郑州大学第二附属医院胸外科,郑州450014

出　　处：《中华实用诊断与治疗杂志》2013年第10期951-953,共3页Journal of Chinese Practical Diagnosis and Therapy

基　　金：国家自然科学基金资助项目(No.81172874)

摘　　要：目的评估尿脱落细胞学及荧光原位杂交技术(fluorescence in situ hybridization,FISH)检测在筛查尿路上皮癌中的特异性及敏感性,分析各畸变染色体与尿路上皮癌的关系。方法对156例血尿患者(血尿组)和20例体检健康者(对照组)分别行普通细胞学和FISH检测。以手术或组织活检病理检测结果验证FISH检测技术及细胞学检测结果的准确性,比较2种检测技术在尿路上皮癌筛查中的敏感性和特异性,分析3、7、17号染色体及p16位点在尿路上皮癌中的畸变概率。结果血尿组FISH检测和尿脱落细胞学检测诊断尿路上皮癌的敏感性分别为91.6%和40.2%,二者比较差异有统计学意义(χ2=33.802,P=0.000);特异性分别为95.9%和97.7%,二者比较差异无统计学意义(P>0.05);3、7、17号染色体及p16位点畸变的概率分别为63.0%、64.1%、67.4%、75.0%。结论 FISH检测可明显提高尿路上皮癌术前诊断准确性,可了解尿路上皮癌患者尿脱落细胞染色体畸变情况。Objective To assess the specificity and sensitivity of fluorescence in situ hybridization （FISH） technique to the diagnosis of urothelial carcinoma, and explore the relationship of chromosome aberration with urothelial carcinoma. Methods FISH and cytology technique were used in 156 patients with haematuria and 20 normal controls. The accuracies of them were tested by operation or pathology results. The sensitivity and specificity of FISH were evaluated and compared with cytology technique. The aberration rates of chromosome CSP3, CSP7, CSP17 and GLPpl6 were analyzed. Results The sensitivities of FISH and cytology technique for the urothelial carcinoma were 91. 6% and 40. 2% in haematuria patients, which showed a significant difference （χ2= 33. 802, P= 0. 000）. There was no significant difference in the specificities between FISH （95. 9%） and cytology technique （97. 7%）（P〈 0. 05）. The aberration rates of chromosome CSP3, CSP7, CSP17 and GLPp16 were 63.0%, 64.1%, 67.4% and 75.0%. Conclusion FISH technique improves the diagnostic accuracy of urothelial carcinoma before operation, and shows the chromosome aberration status in urinary exfoliated cells in the urothelial carcinoma patients.

关 键 词：尿路上皮癌 荧光原位杂交技术 普通细胞学检测技术 

分 类 号：R737.14[医药卫生—肿瘤]